Drug Trial Radar · NCT05224141
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
Last checked: Nov 19, 2026Latest source record: Jul 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
460
Actual
Start
Mar 24, 2022
Primary completion
Jun 4, 2024
Study completion Jun 7, 2027
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Feb 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The primary hypothesis is, with respect to overall survival, MK-7684A in combination with the background therapy of etoposide/platinum followed by MK-7684A, is superior to atezolizumab in combination with the background therapy of etoposide/platinum followed by atezolizumab.
Conditions
- Small Cell Lung Carcinoma
Interventions
Pembrolizumab/Vibostolimab Co-FormulationBiological
Pembrolizumab 200 mg plus vibostolimab 200 mg fixed dose coformulation administered via IV infusion Q3W on Day 1 of each cycle until discontinuation criteria are met.
Saline placeboDrug
Saline solution administered via IV infusion on Cycle 1 (and Q3W as needed beyond Cycle 1)
EtoposideDrug
Etoposide 100 mg/m\^2 administered via IV infusion Q3W on Days 1 2, 3 of each cycle for up to 4 cycles
CisplatinDrug
Cisplatin 75 mg/m\^2 administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
AtezolizumabBiological
Atezolizumab 1200 mg administered via IV infusion Q3W on Day 1 of each cycle until discontinuation criteria are met.
CarboplatinDrug
Carboplatin AUC 5 mg/mL/min administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to approximately 25 months
Locations
140 sites in 25 countries. Site status is shown where the registry gives one.
Infirmary Cancer Care ( Site 0022)
Mobile, Alabama
Los Angeles Hematology Oncology Medical Group ( Site 0006)
Los Angeles, California
VA West Los Angeles Medical Center ( Site 0004)
Los Angeles, California
Boca Raton Regional Hospital-Lynn Cancer Institute ( Site 0014)
Boca Raton, Florida
Fort Wayne Medical Oncology and Hematology ( Site 0013)
Fort Wayne, Indiana
Dana-Farber Cancer Institute ( Site 0018)
Boston, Massachusetts
Cancer and Hematology Centers of Western Michigan ( Site 0001)
Grand Rapids, Michigan
Hattiesburg Clinic Hematology/Oncology ( Site 0003)
Hattiesburg, Mississippi
Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0005)
Lancaster, Pennsylvania
Blue Ridge Cancer Care ( Site 0015)
Blacksburg, Virginia
University of Virginia Cancer Center ( Site 0019)
Charlottesville, Virginia
Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0203)
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0201)
Mar del Plata, Buenos Aires, Argentina
Centro de Educación Médica e Investigaciones Clínicas (CEMIC)-Medical Oncology ( Site 0200)
Buenos Aires, Buenos Aires F.D., Argentina
Hospital Provincial del Centenario ( Site 0205)
Rosario, Santa Fe Province, Argentina
Sanatorio Parque ( Site 0202)
Rosario, Santa Fe Province, Argentina
Nepean Hospital ( Site 2700)
Kingswood, New South Wales, Australia
Calvary Mater Newcastle ( Site 2703)
Waratah, New South Wales, Australia
Frankston Hospital-Oncology and Haematology ( Site 2702)
Frankston, Victoria, Australia
Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 2701)
Melbourne, Victoria, Australia
Standort Penzing der Klinik Ottakring-Abteilung für Atemwegs-und Lungenkrankheiten ( Site 0502)
Vienna, Austria
Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 0501)
Vienna, Austria
Medizinische Universität Graz ( Site 0504)
Graz, Styria, Austria
Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 0505)
Linz, Upper Austria, Austria
Kepler Universitätsklinikum ( Site 0507)
Linz, Upper Austria, Austria
Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 0106)
Kingston, Ontario, Canada
Lakeridge Health ( Site 0102)
Oshawa, Ontario, Canada
Anhui Cancer Hospital ( Site 2915)
Hefei, Anhui, China
Beijing Cancer hospital-Thoracic Cancer Department A ( Site 2901)
Beijing, Beijing Municipality, China
Beijing Peking Union Medical College Hospital ( Site 2921)
Beijing, Beijing Municipality, China
Fujian Provincial Cancer Hospital-oncology department ( Site 2904)
Fuzhou, Fujian, China
Harbin Medical University Cancer Hospital-oncology of department ( Site 2920)
Harbin, Heilongjiang, China
Henan Cancer Hospital ( Site 2916)
Zhengzhou, Henan, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology-Medical Oncology ( Site 2912)
Wuhan, Hubei, China
Hubei Cancer Hospital ( Site 2922)
Wuhan, Hubei, China
Hunan Cancer Hospital ( Site 2907)
Changsha, Hunan, China
The First Affiliated Hospital of Soochow University ( Site 2913)
Suzhou, Jiangsu, China
Jilin Cancer Hospital-GCP office ( Site 2909)
Changchun, Jilin, China
The First Hospital of Jilin University ( Site 2914)
Changchun, Jilin, China
The First Affiliated Hospital of Xi'an Jiaotong University-Oncology ( Site 2910)
Xi'an, Shaanxi, China
Showing 40 of 140 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.